| Authors | Title | Date | Links/Downloads |
|---|---|---|---|
| Middleton M.R. | Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potentially Activated Antitumour Immune Responses in Patients with Metastatic Melanoma | 2020-08 | View |
| Fergusson J.R. | Epub ahead of print: Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells | View | |
| Coles C.H., Mulvaney R.M. | T cell receptors with distinct specificity profiles use different binding modes to engage an identical peptide-HLA complex. J Immunol. 2020 Apr 1;204(7):1943-1953. | 2020-02 | View |
| Damato B.E. | Tebentafusp: T Cell Redirection for the Treatment of Advanced Uveal Melanoma. Cancers 2019 Jul 11;11(7). pii: E971. | 2019-07 | View |
| Madura F. | TCR-induced alteration of primary MHC peptide anchor residue. Eur. J. Immunol. 2019 Jul;49(7):1052-1066. | 2019-05 | View |
| Lowe K.L. | Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treat Rev. 2019 Jul;77:35-43. | View | |
| Dobrzycki T., Ciuntu A. | Assessing the potency of T cell redirecting therapeutics using in vitro cancer cell killing assays. Immuno-Oncology: Cellular and Translational Approaches, Springer Methods. 2019 | 2019-01 | |
| Sato T, et al. | Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T cell based toxicity and preliminary efficacy in advanced uveal melanoma (2017) ASCO. | 2017-05 | News article |
| Carvajal, R, et al. | Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (2017) SITC. | News article | |
| Boudousquie C. et al. | Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells (2017) Immunology. 152(3):425-438. | PubMed | |
| Middleton, R M. | Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific T cell redirector with solid tumour activity: Results from the FIH study in melanoma (2016) ASCO. | 2016-05 | News article |
| Bossi G. et al. | ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. (2014) Cancer Immunol Immunother. 63(5):437-48. | PubMed | |
| Bossi G. et al. | Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells. (2013) Oncoimmunology. Nov 1;2(11):e26840. | PubMed | |
| Oates J. et al. | ImmTACs for targeted cancer therapy: Why, what, how, and which (2015) Mol Immunol. 67(2 Pt A):67-74. | PubMed | |
| McCormack E. et al. | Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. (2013) Cancer Immunol Immunother 62(4):773-85. | PubMed | |
| Oates J. and Jakobsen B.K. | ImmTACs: Novel bi-specific agents for targeted cancer therapy. (2013) Oncoimmunology 2(2):1-2. | PubMed | |
| Liddy N. et al. | Monoclonal TCR-redirected tumor cell killing. (2012) Nat Med 18(6):980-7. | PubMed | |
| Yang H. et al. | Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune mobilising T cell receptors. (2016) Molecular Therapy. 24(11):1913-1925. | PubMed | |
| Liddy N. et al. | Production of a soluble disulfide bond-linked TCR in the cytoplasm of Escherichia coli trxB gor mutants. (2010) Mol Biotechnol 45(2):140-9. | PubMed | |
| Dunn S.M. et al. | Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. (2006) Protein Sci 15(4):710-21. | PubMed | |
| Li Y. et al. | Directed evolution of human T-cell receptors with picomolar affinities by phage display. (2005) Nat Biotechnol 23(3):349-54. | PubMed | |
| Ashfield R. and Jakobsen B.K. | Making high-affinity T-cell receptors: a new class of targeted therapeutics. (2006) IDrugs 9(8):554-9. | PubMed | |
| Boulter J.M. and Jakobsen B.K. | Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens. (2005) Clin Exp Immunol 142(3):454-60. | 2005-12 | PubMed |
| Boulter J.M. et al. | Stable, soluble T-cell receptor molecules for crystallization and therapeutics. (2003) Protein Eng 16(9):707-11. | 2003-09 | PubMed |
| Sami M. et al. | Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. (2007) Protein Eng Des Sel 20(8):397-403. | PubMed | |
| Raman, M. C. et al. | Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. (2016) Sci Rep 6. 18851. | PubMed | |
| Cameron B.J. et al. | Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. (2013) Sci Trans Med Aug 7;5(197):197ra103. | PubMed | |
| Hickman, E. S. et al. | Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. (2016) J Biomol Screen. 21(8):769-85. | PubMed | |
| Purbhoo M.A. et al. | Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. (2006) J Immunol 176(12):7308-16. | PubMed | |
| Lissin N. et al. | High-Affinity Monoclonal T-cell receptor (mTCR) Fusions. Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges. (2013). | Wiley | |
| Hassan N.J. and Oates J. | The T Cell Promise. (2013) European Biopharmaceutical Review (Summer 2013). | 2013-12 | View |
| Aleksic M. et al. | Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. (2012) Eur J Immunol 42(12):3174-9. | PubMed | |
| Sato T, et al. | Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-direct TCR IMCgp100: Overall survival findings (2018) ASCO. | News article | |
| Patel M et al. | iS-CellR: a user-friendly tool for analyzing and visualizing single-cell RNA sequencing data (2018). Bioinformatics. | PubMed | |
| Harper J, et al. | An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules (2018). PLOS One. | PubMed | |
| Crean R., et al. | Reliable In Silico Ranking of Engineered Therapeutic TCR Binding Affinities with MMPB/GBSA. J Chem Inf Model 2022; 62(3): 577-590 | 2022-01 | View |
| Weaver E., et al. | Microfluidic-mediated self-assembly of phospholipids for the delivery of biologic molecule. Int J Pharm 2022; 611: 121347 | 2022-01 | View |
| Barber, C., et al. | Structure-guided stabilization of pathogen-derived peptide-HLA-E complexes using non-natural amino acids conserves native TCR recognition. Eur J Immunol 2022; 52(4): 618-632 | 2022-02 | View |
| Carvajal, R. D., et al. | Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol 2022; 40(17): 1939 | 2022-03 | View |
| Hopkins J.R., et al. | Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement. Discov Immunol 2022; 1(1) kyac001 | 2022-05 | View |
| Poole, A. et al. | Therapeutic high affinity T cell receptor targeting a KRAS<sup>G12D</sup> cancer neoantigen. Nat Comms 2022; 13(1): 5333 | 2022-09 | View |
| Carvajal, R. D. et al. | Clinical and molecular response to tebentafusp in previously-treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med 2022; 28(11): 2364-2373 | 2022-10 | View |
| Wallace Z. et al. | Combination strategies to durably suppress HIV-1: Soluble T cell receptors. J Virus Erad 2022; 8(3): 100082 | 2022-09 | View |
| Wallace Z. et al. | Immune mobilising T cell receptors redirect polyclonal CD8+ T cells in chronic HIV infection to form immunological synapses. Sci Rep 2022; 12(1):18366 | 2022-11 | View |
| Salio, M. | Unconventional MAIT cell responses to bacterial infections. Semin Immunol 2022; 61-64: 101663 | 2022-11 | View |
| Weaver E., et al. | The manufacturing of 3D-printed microfluidic chips to analyse the effect upon particle size during the synthesis of lipid nanoparticles. J Pharm Pharmacol 2022; rgac085 | 2022-12 | View |
| Berman DM, Bell JI. | Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors. Clin Cancer Res. 2023;29(4):697-704 | 2023-02 | View |
| Hamid, O. et al. | Tebentafusp in Combination with Durvalumab and/or Tremelimumab in Patients with Metastatic Cutaneous Melanoma: A Phase 1 Study. J Immunother Cancer. 2023 Jun;11(6):e006747. | 2023-06 | View |
| Chancellor. A. et al. | Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses. J Exp Med 4 September 2023; 220 (9): e20221939. | 2023-06 | View |
| Knezevic. L. et al. | High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs. J Biol Chem. 2023;299(8):104981. | 2023-08 | View |
| Weaver, E., et al. | Microfluidic Encapsulation of Enzymes and Steroids within Solid Lipid Nanoparticles. Drug Deliv Transl Res. 2024;14(1):266-279. | 2023-07 | View |
| Robertson, I.B. et al. | Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Clin Exp Immunol. 2024;215(2):105-119. | 2023-11 | View |
| Hassel, J.C. & Piperno-Neumann, S. et al. | Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023;389(24):2256-2266. | 2023-10 | View |
| Meyer, M. et al. | A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics. Nat Rev Drug Discov. 2024;23(1):1-2 | 2023-11 | View |
| Piulats, JM et al. | Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. Ann Oncol. 2024;35(3):317-326. | 2023-12 | View |
| Wallace Z. et al. | Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting. Mol Ther. 2024;32(3):678-688. | 2024-01 | View |
| Paterson, R. et al. | An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2024;121(19):e2318003121. | 2024-05 | View |
| Sacco JJ, Carvajal RD et al. | Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024;12(6):e009028. | 2024-06 | View |
| Coles, C.H. Mulvaney R.M. et al. | T cell receptors with distinct specificity profiles use different binding modes to engage an identical peptide-HLA complex. J. Immunol. 2020;204(7):1943-1953. | 2020-04 | News article |
| Holland C.J. et al. | Specificity of bispecific TCRs and antibodies targeting peptide-HLA. J. Clin. Invest. 2020;130(5):2673-2688. | 2020-04 | News article |
| Coles C.H., McMurran C. et al. | T Cell Receptor interactions with Human Leukocyte Antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4. J Biol Chem. 2020;295(33):11486-11494. | 2020-08 | News article |
| Crean R.M. et al. | Molecular rules underpinning enhanced affinity binding of T cell receptors engineered for immunotherapy. Mol Ther Oncolytics. 2020;18:443-456. | 2020-09 | News article |
| Fergusson J.R. et al. | Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells. Hepatology. 2020 Nov;72(5):1528-1540. doi: 10.1002/hep.31503. | 2020-11 | News article |
| Middleton M.R. et al. | Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma. Clin Can Res. 2020 Aug 18. doi: 10.1158/1078-0432.CCR-20-1247. | 2020-11 | News article |
| Robinson R.A., McMurran C. et al. | Engineering soluble T-cell receptors for therapy. FEBS Journal 2021 Feb 23. doi: 10.1111/febs.15780. | 2021-02 | News article |
| Orloff M. | Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy. Ocul Oncol Pathol 2021;7:168-176. doi: 10.1159/000513336 | 2021-03 | News article |
| Yang H., et al. | Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses. Cell Rep. 2021 May 11;35(6):109103. doi: 10.1016/j.celrep.2021.109103. | 2021-05 | News article |
| Weaver E., et al. | The Present and Future Role of Microfluidics for Protein and Peptide-Based Therapeutics and Diagnostics. Appl. Sci. 2021, 11(9), 4109; doi: 10.3390/app11094109 | 2021-04 | News article |
| Lanz A-L., et al. | Allosteric activation of T cell antigen receptor signaling by quaternary structure relaxation. Cell Rep. 2021 July 13;36(2):109375. doi: 10.1016/j.celrep.2021.109375 | 2021-07 | News article |
| McDaid W.J. et al. | Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors. Nanoscale. 13(35):15010-15020. doi: 10.1039/d1nr04001d. | 2021-08 | News article |
| McDaid W.J. et al. | Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021 Sep 7;152468. doi: 10.1172/jci.insight.152468. | 2021-09 | News article |
| Nathan P., et al. | Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. | 2021-08 | News article |
| Weaver E., et al. | Microfluidic-Mediated self-assembly of Phospholipids for the delivery of Biologic Molecules. Int J Pharm 2021 Dec 7;611:121347. doi: 10.1016/j.ijpharm.2021.121347. | 2022-01 | News article |
| Hassel JC, Stanhope S, Greenshields-Watson A, et al. | Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J Invest Dermatol. Published online July 15, 2024. | 2024-07 | News article |
| Szoke-Kovacs, R. et al. | Insights into the CD1 lipidome. Front. Immunol. 2024 Aug 22;15:1462209. doi: 10.3389/fimmu.2024.1462209 | 2024-08 | News article |
CM-GL-2400015
Date of production: July 2024